Marina Caligara

Marina Caligara

Auto-generated profile, based on publicly available information

Marina Caligara

Sezione di Tossicologia Forense, Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche; Università degli Studi di Milano; Italy

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2004 in International journal of legal medicine
Verified
Journal Article
Closed access
PDF file
Carlo CampobassoCarlo Campobasso
Carlo Campobasso
MGMirella Gherardi
Mirella Gherardi
MCMarina Caligara
Marina Caligara
LSLuca Sironi
Luca Sironi
FIFrancesco Introna
Francesco Introna

1 August 1996 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
SMS. Mercadante
S. Mercadante
MSM. Sapio
M. Sapio
RSR. Serretta
R. Serretta
MCM. Caligara
M. Caligara
Methadone is a very useful drug in cancer pain because of its low cost, lack of active metabolites, high oral availability, and the rapid onset of its analgesic effect. It seems to be well tolerated in patients with difficult pain syndromes who are receiving high doses of opioids, and it may deter the development of tolerance, but a high individual variation in terminal elimination half-life can result in different rates and extents of drug accumulation. For this reason, oral patient-controlled analgesia with methadone was used in 24 advanced-disease patients with pain. A regimen of self-administered oral methadone at fixed doses and flexible patient-controlled dosage intervals to achieve adequate analgesia, while avoiding toxic effects of methadone accumulation, was used in 24 patients requiring opioid therapy. After a priming period of three days with fixed doses of 3–5 mg three times a day for naïve patients and 50% of the morphine equivalent of methadone in patients switched from morphine, patients and relatives were instructed to maintain the night-time dose and to administer a second dose when the pain recurred. When than four doses of methadone a day were used, an increase of the dosage was prescribed. Continuous pain assessment and monitoring of symptoms were offered. The majority of patients achieved good pain relief until death, and three were switched to very low doses of subcutaneous morphine in their final days. The methadone escalation index was about 2% a day, with a mean dosage increase of 0.3 mg a day for an average of 60 days of treatment at doses ranging from 9 to 80 rug. The plasma concentration in 14 patients ranged from 0.013 to 0.273 mcg/ml with dosages of 20–80 mg during chronic treatment. A mean of 2.4 doses a day was reported, including the fixed night-time dose. The extent of side effects was considered acceptable. Patient-administered analgesia with oral methadone appears to be a simple, cheap and relatively safe technique for controlling cancer pain, permitting individualization by the patient him- or herself and avoiding the risk of accumulation. Continuous assessment is necessary.

1 July 1997 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
SMSebastiano Mercadante
Sebastiano Mercadante
MSMonica Sapio
Monica Sapio
MCMarina Caligara
Marina Caligara
RSRoberto Serretta
Roberto Serretta
GDGabriella Dardanoni
Gabriella Dardanoni
LBLuca Barresi
Luca Barresi

1 April 1997 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
SMSebastiano Mercadante
Sebastiano Mercadante
MCMarina Caligara
Marina Caligara
MSMonica Sapio
Monica Sapio
RSRoberto Serretta
Roberto Serretta
FLFranco Lodi
Franco Lodi

1 December 2008 in American Journal of Forensic Medicine & Pathology
Verified
Journal Article
Closed access
Carlo CampobassoCarlo Campobasso
Carlo Campobasso
RPRossella Procacci
Rossella Procacci
MCMarina Caligara
Marina Caligara
A case of an asthmatic woman who collapsed within a few minutes after intramuscular ketorolac tromethamine (KT) injection is reported. Autopsy findings revealed anatomic evidence of a recent asthma attack. KT was found to be present in the blood at a concentration within the therapeutic range and consistent with the administered dose. Based on the timing of the collapse in relation to the KT administration, death was attributed to an adverse reaction to KT, resulting in acute bronchospasm and cardiac arrest, with asthma as an underlying contributing factor. In this case, asthma alone was not responsible for the death of the patient but only a contributing factor. Physicians have to be aware that in asthmatic patients bronchospasm can be induced by drugs among which aspirin or nonsteroidal anti-inflammatory drugs such as KT are the most common; therefore, death may have an iatrogenic cause. The paper also describes the pathogenic mechanism of an adverse reaction to such drugs and analytical methods for the isolation and detection of KT in postmortem blood.

21 January 2015 in International journal of legal medicine
Verified
Journal Article
Closed access
PDF file
AAAlberto Amadasi
Alberto Amadasi
LMLavinia Mastroluca
Lavinia Mastroluca
LMLaura Marasciuolo
Laura Marasciuolo
MCMarina Caligara
Marina Caligara
LSLuca Sironi
Luca Sironi
RZRiccardo Zoja
Riccardo Zoja